Controlled Comparison of Tianeptine, Alprazolam and Mianserin in the Treatment of Adjustment Disorders with Anxiety and Depression
✍ Scribed by MARC ANSSEAU; MICHEL BATAILLE; GUY BRIOLE; ANDRÉ DE NAYER; PIERRE ANDRÉ FAUCHÈRE; FRANÇOIS FERRERO; CLAUDINE MERTENS; RENZO REALINI; PHILIPPE ROMBAUT; ANDRÉ VEREECKEN; BENOÎT TROISFONTAINES; MYRIAM VAN MOFFAERT
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 439 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
✦ Synopsis
A multicentre study compared tianeptine (37.5 mg/day), an original psychotropic compound characterized by both antidepressant and anxiolytic potentials, with a reference antidepressant, mianserin (60 mgkday) and a reference anxiolytic, alprazolam (1.5 mglday), in the treatment of 152 patients fulfilling DSM-III-R criteria for adjustment disorder with mixed emotional features (anxiety and depression). The study used a double-blind parallel design over a 6-week period. Clinical assessments included the Clinical Global Impressions (CGI), the Montgomery and Asberg depression rating scale (MADRS), the Hamilton anxiety rating scale, a visual analogue scale, and the somatic scale of the system developed by the Association for the Methodology and Documentation in Psychiatry (AMDP). Results showed very similar improvement in the three treatment groups on all rating instruments. Moreover, the number of patients exhibiting adverse events did not differ among the three groups. Therefore, these results show similar antidepressant and anxiolytic activity for tianeptine, mianserin and alprazolam in patients suffering from adjustment disorder with mixed emotional features. These promising findings should however be confirmed in a placebo-controlled trial.
📜 SIMILAR VOLUMES
We studied Levenson's Internal (I), Powerful Others (P), and Chance (C) locus of control scales in 193 patients with six DSM-III-R diagnoses: Major Depression (MD), Panic Disorder (PD), Generalized Anxiety Disorder (GAD), Social Phobia (SP), Obsessive Compulsive Disorder (OCD), and Mixed Anxiety Dep
A multicentre, double-blind, randomized trial compared the ecacy of a sustained-release formulation of alprazolam with bromazepam in the treatment of generalized anxiety. One hundred and twenty-one outpatients were randomly assigned to three weeks of active treatment with alprazolam SR (2 mg once da
This double-blind randomized pilot study aimed to compare the ecacy and the tolerability of pirlindole (150±225 mg/day), a reversible inhibitor of monoamine oxidase A, and mianserin (60±90 mg/day) in the treatment of major depression. Forty patients were included in the trial (20 pirlindole and 20 m
Objectives. To compare the ecacy of paroxetine and imipramine prospectively in patients with coexisting depression and dementia. Methods. An 8-week, double-blind, parallel group trial comparing paroxetine 20±40 mg/day with imipramine 50±100 mg/day in 198 patients aged 60 years or over with a Montgo
This CES review covers published and to be published clinical trials in the English language and reported to be controlled in some fashion and completed from January 1963 to January 1996. Cranial electrotherapy stimulation (CES) is de®ned as the application of low-level pulsed electrical current thr